Improving the Efficacy of Mesenchymal Stem/Stromal-Based Therapy for Treatment of Inflammatory Bowel Diseases

Inflammatory bowel diseases (IBD) consisting of persistent and relapsing inflammatory processes of the intestinal mucosa are caused by genetic, environmental, and commensal microbiota factors. Despite recent advances in clinical treatments aiming to decrease inflammation, nearly 30% of patients trea...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mercedes Lopez-Santalla, Marina Inmaculada Garin
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	inflammatory bowel disease mesenchymal stem/stromal cells improvement protocols Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/294509dff2494d93b2dbd15636a9b0cb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:294509dff2494d93b2dbd15636a9b0cb
record_format	dspace
spelling	oai:doaj.org-article:294509dff2494d93b2dbd15636a9b0cb2021-11-25T16:48:22ZImproving the Efficacy of Mesenchymal Stem/Stromal-Based Therapy for Treatment of Inflammatory Bowel Diseases10.3390/biomedicines91115072227-9059https://doaj.org/article/294509dff2494d93b2dbd15636a9b0cb2021-10-01T00:00:00Zhttps://www.mdpi.com/2227-9059/9/11/1507https://doaj.org/toc/2227-9059Inflammatory bowel diseases (IBD) consisting of persistent and relapsing inflammatory processes of the intestinal mucosa are caused by genetic, environmental, and commensal microbiota factors. Despite recent advances in clinical treatments aiming to decrease inflammation, nearly 30% of patients treated with biologicals experienced drawbacks including loss of response, while others can develop severe side effects. Hence, novel effective treatments are highly needed. Mesenchymal stem/stromal cell (MSCs) therapy is an innovative therapeutic alternative currently under investigation for IBD. MSCs have the inherent capacity of modulating inflammatory immune responses as well as regenerating damaged tissues and are therefore a prime candidate to use as cell therapy in patients with IBD. At present, MSC-based therapy has been shown preclinically to modulate intestinal inflammation, whilst the safety of MSC-based therapy has been demonstrated in clinical trials. However, the successful results in preclinical studies have not been replicated in clinical trials. In this review, we will summarize the protocols used in preclinical and clinical trials and the novel approaches currently under investigation which aim to increase the beneficial effects of MSC-based therapy for IBD.Mercedes Lopez-SantallaMarina Inmaculada GarinMDPI AGarticleinflammatory bowel diseasemesenchymal stem/stromal cellsimprovement protocolsBiology (General)QH301-705.5ENBiomedicines, Vol 9, Iss 1507, p 1507 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	inflammatory bowel disease mesenchymal stem/stromal cells improvement protocols Biology (General) QH301-705.5
spellingShingle	inflammatory bowel disease mesenchymal stem/stromal cells improvement protocols Biology (General) QH301-705.5 Mercedes Lopez-Santalla Marina Inmaculada Garin Improving the Efficacy of Mesenchymal Stem/Stromal-Based Therapy for Treatment of Inflammatory Bowel Diseases
description	Inflammatory bowel diseases (IBD) consisting of persistent and relapsing inflammatory processes of the intestinal mucosa are caused by genetic, environmental, and commensal microbiota factors. Despite recent advances in clinical treatments aiming to decrease inflammation, nearly 30% of patients treated with biologicals experienced drawbacks including loss of response, while others can develop severe side effects. Hence, novel effective treatments are highly needed. Mesenchymal stem/stromal cell (MSCs) therapy is an innovative therapeutic alternative currently under investigation for IBD. MSCs have the inherent capacity of modulating inflammatory immune responses as well as regenerating damaged tissues and are therefore a prime candidate to use as cell therapy in patients with IBD. At present, MSC-based therapy has been shown preclinically to modulate intestinal inflammation, whilst the safety of MSC-based therapy has been demonstrated in clinical trials. However, the successful results in preclinical studies have not been replicated in clinical trials. In this review, we will summarize the protocols used in preclinical and clinical trials and the novel approaches currently under investigation which aim to increase the beneficial effects of MSC-based therapy for IBD.
format	article
author	Mercedes Lopez-Santalla Marina Inmaculada Garin
author_facet	Mercedes Lopez-Santalla Marina Inmaculada Garin
author_sort	Mercedes Lopez-Santalla
title	Improving the Efficacy of Mesenchymal Stem/Stromal-Based Therapy for Treatment of Inflammatory Bowel Diseases
title_short	Improving the Efficacy of Mesenchymal Stem/Stromal-Based Therapy for Treatment of Inflammatory Bowel Diseases
title_full	Improving the Efficacy of Mesenchymal Stem/Stromal-Based Therapy for Treatment of Inflammatory Bowel Diseases
title_fullStr	Improving the Efficacy of Mesenchymal Stem/Stromal-Based Therapy for Treatment of Inflammatory Bowel Diseases
title_full_unstemmed	Improving the Efficacy of Mesenchymal Stem/Stromal-Based Therapy for Treatment of Inflammatory Bowel Diseases
title_sort	improving the efficacy of mesenchymal stem/stromal-based therapy for treatment of inflammatory bowel diseases
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/294509dff2494d93b2dbd15636a9b0cb
work_keys_str_mv	AT mercedeslopezsantalla improvingtheefficacyofmesenchymalstemstromalbasedtherapyfortreatmentofinflammatoryboweldiseases AT marinainmaculadagarin improvingtheefficacyofmesenchymalstemstromalbasedtherapyfortreatmentofinflammatoryboweldiseases
_version_	1718412944617766912

Improving the Efficacy of Mesenchymal Stem/Stromal-Based Therapy for Treatment of Inflammatory Bowel Diseases

Ejemplares similares